<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698474</url>
  </required_header>
  <id_info>
    <org_study_id>BN102018</org_study_id>
    <nct_id>NCT03698474</nct_id>
  </id_info>
  <brief_title>Comparison of Different Low Volume Solutions Prior to Colonoscopy</brief_title>
  <official_title>Comparison of Efficiency and Tolerance of Sodium Picosulphate/ Magnesium Citrate, Polyethylene Glycol/Ascorbate and Oral Sulfate Solution Before Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomas Bata Hospital, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculty Hospital Kralovske Vinohrady</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tomas Bata Hospital, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study evaluates the head -to-head efficacy and tolerability of low volume preparations prior
      to colonoscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study: To compare the efficacy and tolerance of sodium picosulphate/magnesium
      citrate, polyethylene glycol/ascorbic acid and oral sulfate formula in a single or split dose
      regimen prior to colonoscopy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Actual">February 12, 2019</completion_date>
  <primary_completion_date type="Actual">February 12, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfactory bowel preparation quality (Aronchick score 1-2)</measure>
    <time_frame>one day</time_frame>
    <description>Aronchick scale (1 -5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel preparation tolerance assessed by Visual Analogue Scale (VAS)</measure>
    <time_frame>one day</time_frame>
    <description>VAS scale 0-10 ( 0- the best, 10 - the worst)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>SPMC-S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPMC-D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEGA-S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEGA-D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SULF-S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SULF-D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natrium picosulfate / Magnesium citrate</intervention_name>
    <description>bowel preparation formula</description>
    <arm_group_label>SPMC-D</arm_group_label>
    <arm_group_label>SPMC-S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene glycol / Ascorbic acid</intervention_name>
    <description>bowel preparation formula</description>
    <arm_group_label>PEGA-D</arm_group_label>
    <arm_group_label>PEGA-S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natrium/ Kalium/ Magnesium sulfate</intervention_name>
    <description>bowel preparation formula</description>
    <arm_group_label>SULF-D</arm_group_label>
    <arm_group_label>SULF-S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects referred to diagnostic or therapeutic colonoscopy

        Exclusion Criteria:

          -  known or suspected bowel obstruction

          -  active bowel inflammation

          -  pregnancy

          -  prior bowel resection

          -  any presence of serious medical conditions ( cardiac, renal, liver disease)

          -  inability to obtain valid data from subject

          -  active bowel bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Kojecky</last_name>
    <role>Principal Investigator</role>
    <affiliation>KNTB Zlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10024</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

